210 related articles for article (PubMed ID: 31843555)
41. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
42. Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity.
Chen D; Chou FJ; Chen Y; Huang CP; Tian H; Wang Y; Niu Y; You B; Yeh S; Xing N; Chang C
J Exp Clin Cancer Res; 2022 Aug; 41(1):235. PubMed ID: 35918767
[TBL] [Abstract][Full Text] [Related]
43. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
44. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
[TBL] [Abstract][Full Text] [Related]
45. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
Chan SC; Selth LA; Li Y; Nyquist MD; Miao L; Bradner JE; Raj GV; Tilley WD; Dehm SM
Nucleic Acids Res; 2015 Jul; 43(12):5880-97. PubMed ID: 25908785
[TBL] [Abstract][Full Text] [Related]
46. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Wang M; Sun Y; Xu J; Lu J; Wang K; Yang DR; Yang G; Li G; Chang C
Int J Cancer; 2018 Jul; 143(1):100-112. PubMed ID: 29396852
[TBL] [Abstract][Full Text] [Related]
47. miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.
Pasqualini L; Bu H; Puhr M; Narisu N; Rainer J; Schlick B; Schäfer G; Angelova M; Trajanoski Z; Börno ST; Schweiger MR; Fuchsberger C; Klocker H
Mol Endocrinol; 2015 Jul; 29(7):1037-54. PubMed ID: 26052614
[TBL] [Abstract][Full Text] [Related]
48. IL-1-conferred gene expression pattern in ERα
Nawas AF; Kanchwala M; Thomas-Jardin SE; Dahl H; Daescu K; Bautista M; Anunobi V; Wong A; Meade R; Mistry R; Ghatwai N; Bayerl F; Xing C; Delk NA
BMC Cancer; 2020 Jan; 20(1):46. PubMed ID: 31959131
[TBL] [Abstract][Full Text] [Related]
49. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein.
Xiao J; Gong AY; Eischeid AN; Chen D; Deng C; Young CY; Chen XM
Prostate; 2012 Oct; 72(14):1514-22. PubMed ID: 22314666
[TBL] [Abstract][Full Text] [Related]
50. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C
Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543
[TBL] [Abstract][Full Text] [Related]
51. Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.
Luo J; Lee SO; Cui Y; Yang R; Li L; Chang C
Oncotarget; 2015 Sep; 6(29):27555-65. PubMed ID: 26342197
[TBL] [Abstract][Full Text] [Related]
52. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
54. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer.
Matin F; Jeet V; Srinivasan S; Cristino AS; Panchadsaram J; Clements JA; Batra J;
Clin Chem; 2019 Jun; 65(6):771-780. PubMed ID: 31018918
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-3619-5p suppresses bladder carcinoma progression by directly targeting β-catenin and CDK2 and activating p21.
Zhang Q; Miao S; Han X; Li C; Zhang M; Cui K; Xiong T; Chen Z; Wang C; Xu H
Cell Death Dis; 2018 Sep; 9(10):960. PubMed ID: 30237499
[TBL] [Abstract][Full Text] [Related]
58. Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion.
Chen J; Sun Y; Ou Z; Yeh S; Huang CP; You B; Tsai YC; Sheu TJ; Zu X; Chang C
EMBO Rep; 2020 Apr; 21(4):e48467. PubMed ID: 32052578
[TBL] [Abstract][Full Text] [Related]
59. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
60. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
